The burgeoning landscape of medication for obesity and type 2 diabetes is currently witnessing considerable excitement surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 receptor agonists, significant variations in their pharmacological profiles and clinical investigation results are emerging. Retatrutide, b

Showing promise in the landscape of excess body fat treatment, retatrutide presents a distinct approach. Different from many current medications, retatrutide functions as a dual agonist, simultaneously targeting both peptides, retatrutide, glp, glp-2,glp-3, bpc-157, glutathione, tesamoreli GLP peptide-1 (GLP-1) and glucose-responsive insulinotropic